**Question:** First line drug for prophylaxis of pneumocystosis is

A. Azithromycin
B. Oral Sulfamethoxazole-Trimethoprim
C. Pneumocystis jirovecii pneumonia (PCP)
D. Atovaquone

**Core Concept:** Pneumocystosis is a disease caused by the fungus Pneumocystis jirovecii (formerly Pneumocystis carinii) that primarily affects immunocompromised individuals. Prophylactic treatment aims to prevent the development of clinical symptoms and complications.

**Why the Correct Answer is Right:** B. Oral Sulfamethoxazole-Trimethoprim (co-trimoxazole) is the first-line drug for prophylaxis of pneumocystosis in immunocompromised patients. This combination drug inhibits the growth of Pneumocystis jirovecii by targeting the folic acid synthesis pathway in the fungus.

**Why Each Wrong Option is Incorrect:**

A. Azithromycin (Option A) is a macrolide antibiotic with anti-inflammatory properties, but it does not specifically target Pneumocystis jirovecii. Its efficacy as a prophylactic agent is less compared to co-trimoxazole.

C. Pneumocystis jirovecii pneumonia (PCP) is the disease caused by Pneumocystis jirovecii, but it does not explain why co-trimoxazole is the first-line drug.

D. Atovaquone is an antifungal drug that inhibits the function of the mitochondrial enzyme cytochrome bc1 complex in Pneumocystis jirovecii, but it is not as effective as co-trimoxazole for prophylaxis and has more side effects.

**Clinical Pearl:** Co-trimoxazole (Option B) is a combination drug that provides a synergistic effect by inhibiting folic acid synthesis in Pneumocystis jirovecii. This makes it the first-line drug for prophylaxis of pneumocystosis in immunocompromised patients, as it has a high efficacy rate, a good safety profile, and is well-tolerated.

**Correct Answer Explanation:**

Pneumocystosis is a condition caused by the infection with Pneumocystis jirovecii, a fungus that primarily affects immunocompromised patients. The first-line treatment for prophylaxis of pneumocystosis involves the use of co-trimoxazole (Option B), a combination of sulfamethoxazole and trimethoprim. This drug works by inhibiting the folic acid synthesis pathway in Pneumocystis jirovecii, which kills or inhibits its growth. Co-trimoxazole has a high efficacy rate, a good safety profile, and is well-tolerated. Although other drugs like atovaquone (Option D) are also used in the treatment of pneumocystosis, they are not as effective as co-trimoxazole for prophylaxis and are associated with more